Shelley Potter, Kerry Avery, Rosina Ahmed, Jana de Boniface, Sanjoy Chatterjee, David Dodwell, Peter Dubsky, Hiroji Iwata, Michael Jiang, Han-Byoel Lee, Mairead MacKenzie, Fiorita Poulakaki, Andrea L Richardson, Karla Sepulveda, Andrew Spillane, Alastair M Thompson, Gustavo Werutsky, Jean L Wright, Nicholas Zdenkowski, Katherine Cowan, Stuart McIntosh
INTRODUCTION: Neoadjuvant systemic anticancer therapy (neoSACT) is increasingly used in the treatment of early breast cancer. Response to therapy is prognostic and allows locoregional and adjuvant systemic treatments to be tailored to minimise morbidity and optimise oncological outcomes and quality of life. Accurate information about locoregional treatments following neoSACT is vital to allow the translation of downstaging benefits into practice and facilitate meaningful interpretation of oncological outcomes, particularly locoregional recurrence...
April 19, 2024: BMJ Open